Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, Hughes EJ, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hussey GD, Mahomed H, Hanekom WA, McShane H. Scriba TJ, et al. Among authors: van der merwe l. J Infect Dis. 2011 Jun 15;203(12):1832-43. doi: 10.1093/infdis/jir195. J Infect Dis. 2011. PMID: 21606542 Clinical Trial.
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA. Scriba TJ, et al. Among authors: van der merwe l. Eur J Immunol. 2010 Jan;40(1):279-90. doi: 10.1002/eji.200939754. Eur J Immunol. 2010. PMID: 20017188 Free PMC article. Clinical Trial.
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA. Abel B, et al. Among authors: van der merwe l. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17. doi: 10.1164/rccm.200910-1484OC. Epub 2010 Feb 18. Am J Respir Crit Care Med. 2010. PMID: 20167847 Free PMC article. Clinical Trial.
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Makhethe L, Janse van Rensburg E, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hawkridge A, Hussey GD, Hanekom WA, McShane H, Mahomed H. Scriba TJ, et al. Among authors: van der merwe l. Am J Respir Crit Care Med. 2012 Apr 1;185(7):769-78. doi: 10.1164/rccm.201108-1548OC. Epub 2012 Jan 26. Am J Respir Crit Care Med. 2012. PMID: 22281831 Free PMC article. Clinical Trial.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Tameris MD, et al. Lancet. 2013 Mar 23;381(9871):1021-8. doi: 10.1016/S0140-6736(13)60177-4. Lancet. 2013. PMID: 23391465 Free PMC article. Clinical Trial.
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.
Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H. Tameris M, et al. Among authors: van der merwe l. Tuberculosis (Edinb). 2013 Mar;93(2):143-9. doi: 10.1016/j.tube.2013.01.003. Epub 2013 Feb 12. Tuberculosis (Edinb). 2013. PMID: 23410889 Free PMC article. Clinical Trial.
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf TA, Reid TD, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Lindestam Arlehamn C, Sette A, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-203 study team. Day TA, et al. Lancet Respir Med. 2021 Apr;9(4):373-386. doi: 10.1016/S2213-2600(20)30319-2. Epub 2020 Dec 8. Lancet Respir Med. 2021. PMID: 33306991 Clinical Trial.
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study.
Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Mendelsohn SC, et al. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. Epub 2021 Apr 13. Lancet Glob Health. 2021. PMID: 33862012 Free PMC article.
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018-19.
Cloete A, Mabaso M, Savva H, van der Merwe LL, Naidoo D, Petersen Z, Kose Z, Mthembu J, Moyo S, Skinner D, Jooste S, Fellows IE, Shiraishi RW, Mwandingi SL, Simbayi LC. Cloete A, et al. Among authors: van der merwe ll. Lancet HIV. 2023 Jun;10(6):e375-e384. doi: 10.1016/S2352-3018(23)00059-0. Epub 2023 Apr 26. Lancet HIV. 2023. PMID: 37119825
245 results